LETTERS FOR ISSUE ON
|
|
|
- Godfrey Woods
- 5 years ago
- Views:
Transcription
1 S FOR ISSUE ON INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD APPROVAL (F-RC) 2. M/S. GENETIX BIOTECH ASIA PVT. LTD APPROVAL (F-IL) 3. M/S. BAUSCH & LOMB INDIA PVT. LTD M/S. ENCARTA PHARMA PVT. LTD QUERY 5. M/S. FUSION MEDICAL & DENTAL TECHNOLOGY CO QUERY 6. M/S. HALYARD HEALTH INDIA PVT. LTD QUERY 7. M/S. HALYARD HEALTH INDIA PVT. LTD QUERY 8. M/S. JOHNSON & JOHNSON PVT. LTD QUERY 9. M/S. SMITHS MEDICAL INDIA PVT. LTD QUERY 10. THE DRUGS LICENSING & CONTROLLING AUTHORITY, LUCKNOW (CLAA), THE DEPUTY DRUGS CONTROLLER (I), GHAZIABAD (CLAA) ( M/S. GPC MEDICAL LTD., GHAZIABAD ) FTS. NO QUERY 11. M/S. CLAIRVOYANCE CONSULTING M/S. SHREYAAS HEALTHCARE M/S. SHREYAAS HEALTHCARE M/S. KENTRON BIOTECHNOLOGY PVT. LTD
2 15. M/S. JOHNSON & JOHNSON PVT. LTD M/S. SANDOR MEDICAIDS PVT. LTD DIAGNOSTICS DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. EMERGO (INDIA) CONSULTING PVT. LTD QUERY 2. M/S. NUCLEUS INC QUERY 3. M/S. SIEMENS LIMITED FTS. NO QUERY 4. M/S. SIEMENS LIMITED NIL FDC DIVISION S.NO. NAME OF COMPANY DIARY NO DOCUMENT 1. M/S. ZUVENTUS HEALTHCARE LTD., M/S. SUN PHARMA LABORATORIES SITE ADDITION 3. M/S. D.M. PHARMA M/S. RAVENBHEL HEALTHCARE CLARIFICATION 5. M/S. BLISS GVS PHARMA M/S. FDC LTD., NIL 7. M/S. GLENMARK PHARMACEUTICALS LTD., NIL CLARIFICATION 8. M/S. THEON PHARMACEUTICALS CLARIFICATION 9. M/S. ZUVENTUS HEALTHCARE LTD., NIL 10. M/S. CENTAUR PHARMACEUTICALS NIL
3 11. M/S. MEDLEY PHARMACEUTICALS NIL 12. M/S. UNIMED TECHNOLOGIES LTD., 6871/8298 APPROVAL 13. M/S. SUN PHARMA LABORATORIES NIL SEC 14. M/S. THEON PHARMACEUTICALS NIL SEC SUBSEQUENT NEW DRUG S. NO. NAME OF THE FIRM REFERENCE NO. FTS NO. TYPE OF 1. M/S INTAS - - SEC PHARMACEUTICALS 2. M/S IPCA - - SEC (3) 3. M/S MYLAN - - SEC 4. M/S NOVARTIS - - SEC 5. M/S KUSUM - - SEC HEALTHCARE 6. M/S INVENTIA - - SEC 7. M/S VIRCHOW - - SEC 8. M/S RUSAN - - SEC 9. M/S CIPLA - - SEC 10. M/S TROIKAA - - SEC (2) 11. M/S AKUMS - - SEC 12. M/S SUN PHARMA - - SEC IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. BIOSYNTH INDIA APPROVAL 2. PHAROSE REMEDIES LIMITED APPROVAL 3. MEDI PHARMA DRUG HOUSE APPROVAL 4. MEDI PHARMA DRUG HOUSE APPROVAL 5. MEDOPHARM PRIVATE LIMITED APPROVAL 6. B.M.CHEMIE APPROVAL 7. PRADIPKUMAR & CO APPROVAL 8. PRADIPKUMAR & CO APPROVAL 9. HINDUSTAN CHEMICALS & PHARMACEUTICALS CLARIFICATION
4 10. EASTERN CHEMICALS (MUMBAI) CLARIFICATION PVT. LTD. 11. KARNATAKA ANTIBIOTIC & CLARIFICATION PHARMACEUTICALS LTD. 12. SYMBIO GENERRRICS INDIA PVT. NIL CLARIFICATION LTD 13. MICRO LABS LTD CLARIFICATION 14. HARSHADA CORPORATION 32382, CLARIFICATION REGISTRATION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. RATNAKAR IMPORTS LLP APPROVAL 2. ABBOTT INDIA LTD AMENDED 3. ALLIED PHARMA SOLUTION CLARIFICATION 4. BAYER PHARMACEUTICALS PVT CLARIFICATION LTD. 5. NOVARTIS HEALTHCARE PVT. LTD CLARIFICATION 6. DAEWOONG PHARMACEUTICAL CLARIFICATION PVT. LTD. 7. MSD PHARMACEUTICALS PVT. LTD CLARIFICATION 8. VITUS GLOBAL INC CLARIFICATION VACCINE DIVISION S. NO. COMPANY NAME DY. NO STATUS 1 M/S FERRING PHARMACEUTICALS PVT, LTD 2 M/S PAVIOUR PHARMACEUTICALS PVT, LTD CLARIFICATION CLARIFICATION 3 M/S WOCKHARDT LTD CLARIFICATION 4 M/S ROCHE PRODUCTS INDIA PVT, LTD 5 M/S BHARAT BIOTECH INTERNATIONAL LTD ACKNOWLEDGE ACKNOWLEDGE 6 M/S RELIANCE LIFE SCIENCES INVITATION
5 PVT, LTD 7 M/S BHARAT SERUM AND VACCINE LTD 8 M/S NOVO NORDISK INDIA PVT, LTD 9 M/S SHANTHA BIOTECHNICS LTD INVITATION INVITATION INVITATION 10 M/S GSK PVT, LTD INVITATION BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. *M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT. LTD., NAVI MUMBAI *M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT. LTD., NAVI MUMBAI *M/S. ALKEM LABORATORIES LTD., TALOJA , TAL: PANVEL, DIST: RAIGAD 4. *M/S. ALKEM LABORATORIES LTD., TALOJA , TAL: PANVEL, DIST: RAIGAD 5. *M/S. ALKEM LABORATORIES LTD., TALOJA , TAL: PANVEL, DIST: RAIGAD 6. *M/S. ALKEM LABORATORIES LTD., TALOJA , TAL: PANVEL, DIST: RAIGAD 7. *M/S. ANACIPHER CLINICAL RESEARCH ORGANISATION (A DIVISION OF INDOCO CLARIFICATION APPROVAL CLARIFICATION APPROVAL APPROVAL APPROVAL APPROVAL
6 REMEDIES LTD.), HYDERABAD *M/S. ANACIPHER CLINICAL RESEARCH ORGANISATION, HYDERABAD M/S. APL RESEARCH CENTER, HYDERABAD *M/S. APOTEX RESEARCH PVT. LTD., BANGALORE *M/S. APOTEX RESEARCH PVT. LTD., BANGALORE M/S. AZIDUS LABORATORIES LTD., CHENNAI *M/S. CIPLA LIMITED, MUMBAI *M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD *M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD *M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD *M/S. CLIANTHA RESEARCH LIMITED, AHMEDABAD M/S. DR. REDDY S LABORATORIES LTD., HYDERABAD M/S. DR. REDDY'S LABORATORIES LTD., HYDERABAD CLARIFICATION CLARIFICATION CLARIFICATION APPROVAL CLARIFICATION CLARIFICATION CLARIFICATION APPROVAL APPROVAL APPROVAL APPROVAL CLARIFICATION
7 20. *M/S. FAMY CARE LTD., MUMBAI M/S. GLENMARK PHARMACEUTICALS LTD., NAVI MUMBAI M/S. HETERO LABS LTD., HYDERABAD M/S. HETERO LABS LTD., HYDERABAD M/S. KUSUM HEALTHCARE PVT. LTD., NEW DELHI *M/S. LAMBDA THERAPEUTIC RESEARCH LTD., AHMEDABAD *M/S. LAMBDA THERAPEUTIC RESEARCH LTD., AHMEDABAD *M/S. LAMBDA THERAPEUTIC RESEARCH LTD., AHMEDABAD M/S. MACLEODS PHARMACEUTICALS LTD., ANDHERI (EAST), MUMBAI *M/S. MANIPAL ACUNOVA LIMITED, MANIPAL *M/S. MANIPAL ACUNOVA LTD., MANGALORE M/S. MICRO THERAPEUTIC RESEARCH LABS PVT. LTD., CHENNAI M/S. MYLAN LABORATORIES LIMITED, BANGALORE CLARIFICATION APPROVAL CLARIFICATION APPROVAL 5866 APPROVAL CLARIFICATION REJECTION TEST LICENCE APPROVAL TEST LICENCE CLARIFICATION CLARIFICATION REJECTION
8 33. M/S. PAR BIOSCIENCES PRIVATE LIMITED, CHENNAI *M/S. SEMLER RESEARCH CENTER PVT. LTD., BANGALORE APPROVAL APPROVAL 35. *M/S. SIDMAK LABORATORIES (INDIA) PVT. LTD., VALSAD FTS NO CLARIFICATION 36. *M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD *M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD *M/S. WATSON PHARMA PVT. LTD., NAVI MUMBAI APPROVAL APPROVAL APPROVAL *Above letters sent via also.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
LETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.05.2016 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH MUMBAI-400709 2. M/S. ACCUTEST RESEARCH MUMBAI-400709 3. M/S. ACCUTEST RESEARCH MUMBAI-400709
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.07.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY TYPE OF NO. 1. M/S. CIREX PHARMACEUTICALS LTD - QUERY 2. M/S. LUPIN LIMITED - ADDITIONAL SITES REGISTRATION S.NO. NAME OF APPLICANT DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
LETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
TODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.10.2017 MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14608 QUERY 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14609 QUERY 3. DR. ULHAS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 19.06.2015 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT., NAVI MUMBAI-400 709 2. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
LETTERS FOR ISSUE ON
LETTERS FOR ISSUE ON 27.12.2017 LVP DIVISION S. NO. COMPANY NAME FTS NO. /Diary No. STATUS 01 M/s. Akums Drugs & Pharmaceuticals, Haridwar 02 M/s. Unique Pharmaceutical Laboratories,Guj. (License No.4)
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
New Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Recommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
1 Agio Pharmaceuticals Limited 15/31/2013-EP(Engg) dt:21.11.2013 7,98,217.00 2 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg) dt:21.11.2013 15,10,268.00 3 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg)
Minimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin Clopidogrel Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
Recent trends and challenges
INTERNATIONAL CONFERENCE ON Recent trends and challenges in Bioanalysis Tentative Program Bioanalytica-2017 Hyderabad,India JUNE 30, 2017 Invitation ABC Biologics welcomes you to attend the international
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
Case 2:09-cv DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95. Of Counsel:
Case 2:09-cv-01302-DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza Newark, NJ 07102 (973) 286-6700 clizza@saul.com Attorneys for Plaintiff
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 19 Apr 2019 13:49:20 GMT) CTRI Number CTRI/2009/091/000126 [Registered on: 15/04/2009] - Last Modified On 03/09/2014 Post Graduate Thesis Type of Trial
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 09 Mar 2019 16:29:06 GMT) CTRI Number CTRI/2010/091/000679 [Registered on: 23/08/2010] - Last Modified On 10/07/2015 Post Graduate Thesis Type of Trial
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 02 Sep 2018 23:38:24 GMT) CTRI Number Last Modified On 05/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Companies Database, Mobile Database, Id Database, Credit
m All India Database We Provides Database Companies Database, Mobile Database, Email Id Database, Credit Card Holder Database, Corporate database, CEO s Database, Corporate Employee Database, Car s Owner
Dataset : PharmaTrac MAT MAY PharmaTrac Overview MAY 18
PharmaTrac Overview MAY 18 8434 8956 9655 10422 8112 8917 9549 8258 8921 9406 8668 9630 9381 8662 8373 8999 9013 9796 10413 8742 9315 10050 8458 9180 8601 9092 9767 8364 9145 10583 10173 10387 10217 10476
Case 3:15-cv PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
Case 3:15-cv-05982-PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 Liza M. Walsh Christine I. Gannon CONNELL FOLEY LLP One Newark Center 1085 Raymond Boulevard, 19th Floor Newark, New Jersey
Recommendations: Agend a no. Recommendations. Institute. New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml
: I approve the minutes of 32 nd SEC (Antimicrobial, Antiviral, Antiparasitic and Antifungal) held on 11.04.2017 at CDSCO HQ New Delhi and recommended the following: Agend New Drugs Division 1 12-34/12-DC
10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Narcotics Control Bureau
Narcotics Control Bureau 2 MARCH - 2015 MARCH - 2015 3 Narcotics Control Bureau SN Date Zone/Sub Zone Drug Seized Qty.(Kg) Indians Arrested 1 31.01.2015 Ahmedabad Alprazolam tab 272.522 Methylphenidate
Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 10 Oct 2018 02:19:24 GMT) CTRI Number Last Modified On 06/11/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)
Edition: Version 11-19th of July 2018 List of A & B Products List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities) As from the version
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016 RECOMBINANT PRODUCTS S. No. Firm Name of Formulation Import License No. &
### About Bharat Biotech
Press Release Bharat Biotech Bharat Biotech Launches Typbar-TCV, world s first clinically proven typhoid conjugate vaccine for infants 6 months & older and Adults The new vaccine brings hope to millions
Education. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
Hyderabad, India Delegates. April 27, Tentative program A comprehensive Bioanalysis conclave. Key notes.
INTERNATIONAL CONFERENCE &EXHIBITION Tentative program A comprehensive Bioanalysis conclave 7+ Key notes 50+ Poster presentations 100+ Delegates 2 + Panel Discussions April 27, 2018 Hyderabad, India Invitation
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
Ameya works predominantly in the architectural design, interiors and project management segments in healthcare industry
Introduction Ameya design is premier health care consultancy firm with experience with design and execution of largest number of private sector health care facility in India. Key Information Ameya works
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Thu, 18 Oct 2018 14:39:26 GMT) CTRI Number Last Modified On 06/04/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Exporting Heart Disease to Developing Countries: India. Zeeshan Ali, Ph.D.
Exporting Heart Disease to Developing Countries: India Zeeshan Ali, Ph.D. Mortality Rate Heart disease is the number one cause of mortality. Accounts for one-fourth of all deaths in India. Source: Gupta
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
New: Li st of TPAs List of TPA's released by IRDA Updated C on Oct lick Here.
TPA List In India // Third Party Administrators for Health Insurance are a link between the insured A Third Party Administrator is the same as an ASO - administrative services only company. The duties
REF/2012/01/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 05 May 2018 05:20:32 GMT) CTRI Number Last Modified On 06/04/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8
LABELLING Page 1 of 8 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Bottle carton label 1. NAME OF THE MEDICINAL PRODUCT Lamivudine 150 mg Tablets * 2. STATEMENT OF ACTIVE SUBSTANCE Each film-coated tablet
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
Global Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
1. Dr. Shyam Agarwal, Joint Secretary, Department of Commerce. 2. Shri A.K. Bamba, Director, Department of Commerce
Minutes of Meeting of Inter Ministerial Committee (IMC) for consideration of proposals for setting up ICDs / CFSs held under Chairmanship of Shri P.K. Chaudhery, Additional Secretary (AS), Department of
Influenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 07 Dec 2018 19:05:34 GMT) CTRI Number CTRI/2009/091/000669 [Registered on: 01/12/2009] - Last Modified On Post Graduate Thesis Type of Trial Type of
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
Decisions taken in the 63 rd Meeting of the Genetic Engineering Approval Committee (GEAC) held on 8 th February 2006.
Decisions taken in the 63 rd Meeting of the Genetic Engineering Approval Committee (GEAC) held on 8 th February 2006. The 63 rd Meeting of the Genetic Engineering Approval Committee was held on 8 th February
AGENDA PAPERS FOR THE EIGHTEENTH MEETING SUB-COMMITTEE ON LARGE ANIMALS (SCLA)
AGENDA PAPERS FOR THE EIGHTEENTH MEETING OF SUB-COMMITTEE ON LARGE ANIMALS (SCLA) DATE : 18.04.2005 TIME : 3 : 00 P.M. VENUE : 8 TH FLOOR, JEEVAN PRAKASH BUILDING, 25, KASTURBA GANDHI MARG, NEW DELHI.
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
Research Article. Consumer Protection Act Awareness? Sikka M 1, Anup N 2, Aradhya S 3, Peter S 4, Acharya S 5
Consumer Protection Act Awareness? Sikka M 1, Anup N 2, Aradhya S 3, Peter S 4, Acharya S 5 Research Article Department of Public Health Dentistry 1 Dr. Mona Sikka MDS, Reader National Institute of Dental
NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
Drug Information services-an Emerging Practice in India A Review
Drug Information services-an Emerging Practice in India A Review Mukesh malik Pharmacy Department, Faculty of Shri Ram Murti Smarg College of Engineering, and Technology The UPT. University Uttar Pradesh,
Pharmacologyonline 2: (2010) Newsletter Narain et al.
Drug Information Services An Emerging Practice In India Dr. P.J.Narain,Mukesh K. Malik*, Babita R.malik Pharmacy Department, Faculty of Shri Ram Murti Smarg College Engineering, Bareilly 243202, INDIA
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 22:54:26 GMT) CTRI Number Last Modified On 11/05/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Solvay in India January, 2014
Solvay in India January, 2014 SOLVAY in India, Innovation and Operational excellence Jodhpur Hichem (JV) Ahmedabad Hichem (JV) Bhiwani Hichem (JV) Delhi Hichem (JV) Solvay R&D center Vadodara Panoli Solvay
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF JUNE-2016 DATE OF HEARING 13.06.2016 1. 934855/05 Opp. AMD-245342 M/s. Ajanta Pharma Limited, Mumbai / Mr. Manoj G. Menda, Mumbai
Varna Suraksha LXi12. Features of the System: Master Console. Specifications:
Varna Suraksha LXi12 Varna Suraksha Rodent Repellers - LXi12 Master Consoles are high frequency signal generators. These signals are fed to the transducers which in turn convert them into high frequency
TOTAL MAT 1,52,81, % Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % प क व रण Pack Description छ प BRAND. क पन Company. S. No. Unique No.
Number of Companies consisting of Market Share of 1% & Above 2 3.1 Adrenaline Injection 1 mg/ml Per ml Sum of MAT value considered for price calculation (in Lakhs) 152.69 Sum of PTR per unit considered
NOTIFICATION NO Different cooling off periods applicable for re-admission to Bureau membership - Publisher Members
Audit Bureau Of Circulations Founder Member : International Federation Audit Bureaux Circulations Wakefield House, Sprott Road, Ballard Estate, Mumbai 400 001 Tel: 2261 18 12 / 2261 90 72. Fax: 2261 88
Central Inspection Plan Using Risk Based Approach Of Vaccine Manufacturing Units for 2017
, follow-up, failure A NORTH ZONE 1 M/s Biomed Pvt. Ltd, C-96, Site I, Bulandshahar Road, Ind. Area, Ghaziabad. 1. Oral Polio Vaccine IP, 2. Vi Typhoid Vaccine (Bio Typh TM ) IP, 3. Haemophilus Type-B
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
Disbursement of MDA Claims to Individual Exporters during (-11) 1 JPN Pharma API China 80,000.00 2 Unique Biotech Limited Bio May 3-6, 80,000.00 3 Titan Biotech Limited Cphi Japan 21st to 23rd April 80,000.00
CAREER AIM POSTGRADUATE TRAINING & EXPERIENCE
Dr. Abhishek Parmar DNB. ( CTVS ), MS, MBBS. Consultant. HCG Hospital. AHMEDABAD CAREER AIM I enjoy the enormous responsibility that caring for a critically ill Cardiac and Thoracic patient entails and
Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings
CBI Global Transparency Reporting Congress, London 4 April 2017 1 2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings London 4-Apr-2017 CBI Global Transparency Reporting Congress,
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
INDICATIVE SEAT MATRIX - NBE FET CENTRALIZED COUNSELING 2016 ADMISSION SESSION ROUND-2
G B Pant Hospital J L Nehru Marg, Delhi Cardiac Anaesthesia 1 Delhi-110002 Indraprastha s Delhi Cardiac Anaesthesia 1 Medanta- The Medicity Sector-38, Gurgaon, Haryana Cardiac Anaesthesia 5 Haryana-122001
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 05 Oct 2018 20:16:50 GMT) CTRI Number Last Modified On 07/08/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
CanAssist-Breast: New test for prediction of risk of recurrence in ER+/Her2- early stage breast cancer patients Manjiri Bakre, Ph.D.
CanAssist-Breast: New test for prediction of risk of recurrence in ER+/Her2- early stage breast cancer patients Manjiri Bakre, Ph.D. Founder and CEO OncoStem Diagnostics Pvt. Ltd. Treatment Decision: HR+/HER2-
Tender no. 114/TNMSC/ENGG/2013, Dt:
Tender no. 114/TNMSC/ENGG/2013, Dt:06.03.2013. Tender for supply and installation of equipment to 114 NBSU (New Born Stabilization Units) at secondary health care institutions Results of Evaluation of
MASOCON ROBOTIC HEAD & NECK ONCOLOGY WORKSHOP Old Territory, New Approach 3D Live Surgical workshop. FREE REGISTRATION Limited to 100 seats
ROBOTIC HEAD & NECK ONCOLOGY WORKSHOP Old Territory, New Approach 3D Live Surgical workshop in association with th Date: Sunday,14 April, 2019 Time: 8:30 am - 4:30 pm th Venue: 6 Floor Auditorium, Fortis
MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERY & CHILDREN TANZANIA FOOD AND DRUGS AUTHORITY P.O.
MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERY & CHILDREN TANZANIA FOOD AND DRUGS AUTHORITY P.O. Box 1253, Dodoma, Tanzania Tel: +255 22 2450751, +255 22 2450512, Fax: +255 22 2450793 Website:
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 31 Mar 2019 14:01:04 GMT) CTRI Number Last Modified On 11/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Case 1:14-cv LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023
Case 1:14-cv-00121-LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABO RA TORIES, INC., FOREST LABO RA TORIES HOLDINGS,